TrialNature medicine2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Paolo Antonio Ascierto et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
178 papers cite itlatest 60 shown
this paperpooled ittrialcites it